Zhou Y - Search Results

1

Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer.

Zeng L, Zhou Y, Xu Q, Huang Z, Song L, Wang Z, Deng L, Wu Y, Liang Y, Liu Z, Gao X, Yi X, He Q, Xia X, Yang H, Zhang X, Yan H, Qin H, Lin S, Yang N, Zhang Y. Zeng L, et al. Among authors: zhou y. Lung Cancer. 2023 Oct;184:107350. doi: 10.1016/j.lungcan.2023.107350. Epub 2023 Aug 28. Lung Cancer. 2023. PMID: 37659241

2

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.

Zhang X, Xiong Y, Xia Q, Wu F, Liu L, Zhou Y, Zeng L, Zhou C, Xia C, Jiang W, Liao D, Xiao L, Liu L, Yang H, Guan R, Li K, Wang J, Lei G, Zhang Y, Yang N. Zhang X, et al. Among authors: zhou y, zhou c. JAMA Netw Open. 2020 Mar 2;3(3):e201226. doi: 10.1001/jamanetworkopen.2020.1226. JAMA Netw Open. 2020. PMID: 32191330 Free PMC article. Clinical Trial.

3

A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.

Zhou Y, Jiang W, Zeng L, Mi J, Song L, Lizaso A, Mao X, Yang N, Zhang Y. Zhou Y, et al. Lung Cancer. 2020 May;143:55-59. doi: 10.1016/j.lungcan.2020.03.019. Epub 2020 Mar 19. Lung Cancer. 2020. PMID: 32208297

4

Concurrent ERBB2 missense mutations D769Y and D742 N Are Novel Acquired Mechanism of Gefitinib Resistance but Responds to Gefitinib plus Pyrotinib.

Zhou Y, Jiang W, Yang N, Zhang Y. Zhou Y, et al. Lung Cancer. 2020 Jun;144:90-91. doi: 10.1016/j.lungcan.2020.04.003. Epub 2020 Apr 13. Lung Cancer. 2020. PMID: 32327210 No abstract available.

5

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report.

Zhou Y, Lizaso A, Mao X, Yang N, Zhang Y. Zhou Y, et al. Ann Transl Med. 2020 Sep;8(17):1099. doi: 10.21037/atm-20-1007. Ann Transl Med. 2020. PMID: 33145318 Free PMC article.

6

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of Chemotherapy.

Zhou Y, Zeng L, Yang N, Zhang Y. Zhou Y, et al. JTO Clin Res Rep. 2020 Feb 11;1(2):100010. doi: 10.1016/j.jtocrr.2020.100010. eCollection 2020 Jun. JTO Clin Res Rep. 2020. PMID: 34589923 Free PMC article. No abstract available.

7

DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.

Alam SK, Zhang Y, Wang L, Zhu Z, Hernandez CE, Zhou Y, Yang N, Lei J, Chen X, Zeng L, Klein MA, Hoeppner LH. Alam SK, et al. Among authors: zhou y. Oncogene. 2022 Jan;41(1):83-98. doi: 10.1038/s41388-021-02028-5. Epub 2021 Oct 21. Oncogene. 2022. PMID: 34675407 Free PMC article.

8

Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.

Zhou Y, Song L, Xu Q, Zeng L, Jiang W, Yang N, Zhang Y. Zhou Y, et al. Lung Cancer. 2022 May;167:58-64. doi: 10.1016/j.lungcan.2022.04.002. Epub 2022 Apr 6. Lung Cancer. 2022. PMID: 35405360

9

The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.

Jiang W, Zhou Y, Zeng L, Xiong Y, Liu L, Zhou C, Yang H, Guo H, Minervini F, Bongiolatti S, Yang N, Zhang Y, Tao M. Jiang W, et al. Among authors: zhou y, zhou c. Transl Lung Cancer Res. 2022 Apr;11(4):647-655. doi: 10.21037/tlcr-22-252. Transl Lung Cancer Res. 2022. PMID: 35529791 Free PMC article.

10

Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer.

Zeng L, Zhou Y, Zhang X, Xu Q, Zhou C, Zeng F, Jiang W, Wang Z, Deng L, Yang H, Liu L, Xiong Y, Zhang B, Yang N, Zhang Y. Zeng L, et al. Among authors: zhou y, zhou c. Lung Cancer. 2023 Apr;178:134-142. doi: 10.1016/j.lungcan.2023.02.017. Epub 2023 Feb 24. Lung Cancer. 2023. PMID: 36858002

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72,162 results

Search Page

Filters